Literature DB >> 9580879

Clinical significance of hepatic HCV RNA in patients with chronic hepatitis C demonstrating long-term sustained response to interferon-alpha therapy.

A Larghi1, A Tagger, A Crosignani, M L Ribero, S Bruno, G Portera, P M Battezzati, M Maggioni, M Fasola, M Zuin, M Podda.   

Abstract

Whether sustained biochemical response and absence of serum HCV RNA in the 6-12 months following suspension of interferon-alpha (IFN-alpha) therapy reflect definitive viral clearance in patients with chronic hepatitis C virus (HCV) infection is controversial. To obtain more information on this topic, HCV RNA was sought in both liver and serum samples of 25 long-term responders who were followed for a median period of 39 months (range 21-79) after discontinuation of IFN-alpha. Liver biopsy was undertaken before and 6 to 12 months after IFN-alpha withdrawal. Liver and serum HCV RNA were tested by a nested polymerase chain reaction. Twenty-two patients (88%) tested negative for both liver and serum HCV RNA, two patients had detectable HCV RNA in both liver and serum, and one patient showed persistent HCV RNA only in the liver. Post-treatment liver histology improved markedly in all patients, including those with viral persistence. During further follow-up, biochemical remission was maintained in all patients except one in whom both serum and liver specimens remained HCV RNA positive. The data indicate that the large majority of long-term responders test negative for HCV RNA in the liver, which suggests definitive eradication of HCV RNA infection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9580879

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  3 in total

1.  Long-term outcomes of chronic hepatitis C patients with sustained virological response at 6 months after the end of treatment.

Authors:  Disaya Chavalitdhamrong; Tawesak Tanwandee
Journal:  World J Gastroenterol       Date:  2006-09-14       Impact factor: 5.742

2.  Living donor liver transplantation from a donor previously treated with interferon for hepatitis C virus: a case report.

Authors:  Masaaki Hidaka; Mitsuhisa Takatsuki; Akihiko Soyama; Hisamitsu Miyaaki; Tatsuki Ichikawa; Kazuhiko Nakao; Takashi Kanematsu; Susumu Eguchi
Journal:  J Med Case Rep       Date:  2011-07-03

3.  High versus standard doses interferon-alpha in the treatment of naïve chronic hepatitis C patients in Taiwan: a 10-year cohort study.

Authors:  Ming-Lung Yu; Chia-Yen Dai; Shinn-Cherng Chen; Li-Po Lee; Ming-Yen Hsieh; Zu-Yau Lin; Ming-Yuh Hsieh; Liang-Yen Wang; Jung-Fa Tsai; Wen-Yu Chang; Wan-Long Chuang
Journal:  BMC Infect Dis       Date:  2005-04-12       Impact factor: 3.090

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.